MediWound Ltd. MDWD
Medicinal Chemicals and Botanical Products · IPO 2014 · data as of November 13, 2026
MediWound Ltd. (MDWD) is a healthcare company listed in the US with a market value of about $186M. In the twelve months to September 30, 2026 it had revenue of $10M and net income of -$24M, a net margin of -235.0%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of -48%.
About MediWound
MediWound is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2014. Revenue went from $601000 in 2015 to $17M in 2025, growth of about 39.7% a year. It was profitable in 1 of the last 10 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $17M | $20M | $19M | $26M | $24M | $22M | $32M | $3M | $2M | $2M |
| Net income | -$24M | -$24M | -$30M | -$7M | -$20M | -$14M | -$9M | $5M | -$1M | -$22M | -$19M |
| Free cash flow | — | -$22M | -$20M | -$17M | -$12M | -$9M | -$8M | $7M | -$13M | -$18M | -$17M |
| EPS (diluted) | $-1.87 | $-1.66 | $-2.10 | $-0.47 | $-1.36 | $-0.94 | $-0.64 | $0.34 | $-0.07 | $-1.54 | $-1.31 |
| Net margin | -235.0% | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% | 15.6% | -31.1% | -887.4% | -1212.1% |
| ROIC | — | -45.8% | -49.2% | -38.2% | -60.4% | — | -121.6% | 29.6% | -34.9% | -115.4% | -204.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $29.67, 130% above the current price; targets range from $25.00 to $36.00; the consensus rating is “Strong buy”; expected EPS is $-2.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does MediWound pay a dividend?
Not currently.
Is MediWound a good stock to buy?
We do not give buy or sell advice. MediWound scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.